Spotfire, Iconix Open Analytical Window on Interaction of Chemicals and the Human Genome
Industry first pairs powerful analytics with chemogenomic database to study all approved drugs and toxicants against 10,000+ human genes
SOMERVILLE, Mass., and MOUNTAIN VIEW, Calif., Aug. 5 /PRNewswire/ -- Leading Guided Analytics(TM) provider Spotfire® Inc. and Iconix Pharmaceuticals, Inc., the industry pioneer in the emerging field of chemogenomics, today jointly announced the upcoming commercial release of the first integrated data and analysis tools that can visually model interactions throughout the entire universe of approved drugs, known toxicants and the 10,000 known genes and drug targets in the human genome that pharmaceutical companies study in the hunt for new drugs.
The companies' three-year partnership integrates Spotfire DecisionSite for Functional Genomics(TM) with Iconix's DrugMatrix(TM) drug profiling and prediction system being developed in partnership with MDS Pharma Services and commercialized as a subscription product by Incyte Genomics. Customers of DrugMatrix and Spotfire's DecisionSite for Functional Genomics will be able to seamlessly work with chemogenomic data using both platforms, as well as apply customized analytical tools developed for the DrugMatrix product. The integration of both products will help speed drug discovery while shaving valuable time off drug development cycles by helping researchers reject potential failures well before clinical trials. Visualizing chemogenomic relationships allows scientists to earmark only the highest quality leads and drug candidates at the earliest, most cost-effective stages of drug discovery and development.
"There is no equivalent, or anything close, for analyzing and visualizing chemogenomic content on this scale," said David O'Reilly, Iconix's chief business officer. "We've linked the world's best visualization to the first and largest set of chemogenomic data, benchmarking rich, deep chemical data against the 10,000 known genes, hundreds of known drug targets and thousands of approved drug compounds and important chemical standards. This is all entirely new to science. Iconix is creating a foundation for understanding how drugs interact with the human body, and Spotfire is creating a visualization bridge to power the scientific analysis of this information."
Chemogenomics, a marriage of chemistry and biology, and the next stage of genomic and proteomic (protein interaction) research, combines information in a form immediately relevant to finding and optimizing drug compounds based on powerful new genomic-based information. As the pioneer in this field, Iconix empowers researchers to predict a compound's potential benefits and liabilities early in the discovery process. Iconix brings insight through an unprecedented collection of genomic, biological and chemical profiles combined with experimental data from expression array and molecular pharmacology studies. Spotfire DecisionSite allows product developers, scientists and researchers to test hypotheses based on hundreds of thousands of data sets from within a dynamic, interactive visual environment. More than 10,000 chemists and biologists use Spotfire DecisionSite at major pharmaceutical and biotech companies throughout the world.
"For all of its rapid scientific advances, the pharmaceutical industry has lacked an integrated, organized view of the vast quantities of chemical and genomic research content," said Ian Dwyer, Spotfire vice president of business development. "Iconix and Spotfire are advancing chemogenomics to an unprecedented level with 'what if' analytics that eliminate unpromising prospects earlier so pharmaceutical companies can focus their efforts on sustainable leads."
About Iconix
Iconix Pharmaceuticals develops integrated technologies that allow life science researchers to discover drug candidates for novel therapeutic targets and predict the potential efficacy, toxicity and other side effects of drug candidates at the earliest stages of drug discovery. Iconix also maintains internal drug discovery and development programs based on novel targets resulting from genomic studies. Iconix has established an ecosystem of collaborators to advance its chemogenomic product development initiatives, including Amersham plc (LSE: NYSE: OSE: AHM) and its Biochip Systems Division, Incyte Genomics, Inc. (Nasdaq: INCY - News), the MDS Pharma Services business of MDS Inc. (TSE: MDS - News; NYSE: MDZ - News), and Essential Therapeutics, Inc. (Nasdaq: ETRX - News). For more information, visit Iconix's web site at www.iconixpharm.com.
About Spotfire
Spotfire®, Inc. provides Guided Analytic(TM) applications and services that empower end-users and their enterprises to make faster, better decisions. Spotfire makes instant sense of the data produced by the hundreds of business processes involved in how products are developed, manufactured, distributed, marketed and sold. More than 400 global 2000 customers and over 16,000 users work with Spotfire products worldwide. The company maintains U.S. headquarters in Somerville, Mass., and European headquarters in Goteborg, Sweden. Additional information can be found at www.spotfire.com.
Contact: David Bailey Ed Marshall
Spotfire Inc. Beaupre & Co. Public Relations Inc.
(617) 702-1809 (603) 559-5816
dbailey@spotfire.com emarshall@beaupre.com
David O'Reilly
Iconix Pharmaceuticals, Inc.
(650) 567-5532
doreilly@iconixpharm.com
SOURCE: Iconix Pharmaceuticals, Inc. |
